Pharmaceutical Biochemistry and Bioanalytics, Pharmaceutical Institute, University of Bonn, An der Immenburg 4, 53121, Bonn, Germany.
BioSolveIT GmbH, An der Ziegelei 79, 53757, Sankt Augustin, Germany.
ChemMedChem. 2021 Jun 7;16(11):1696-1715. doi: 10.1002/cmdc.202100039. Epub 2021 Mar 22.
Heterotrimeric G proteins are classified into four subfamilies and play a key role in signal transduction. They transmit extracellular signals to intracellular effectors subsequent to the activation of G protein-coupled receptors (GPCRs), which are targeted by over 30 % of FDA-approved drugs. However, addressing G proteins as drug targets represents a compelling alternative, for example, when G proteins act independently of the corresponding GPCRs, or in cases of complex multifunctional diseases, when a large number of different GPCRs are involved. In contrast to Gαq, efforts to target Gαi/s by suitable chemical compounds has not been successful so far. Here, a comprehensive analysis was conducted examining the most important interface regions of Gαi/s with its upstream and downstream interaction partners. By assigning the existing compounds and the performed approaches to the respective interfaces, the druggability of the individual interfaces was ranked to provide perspectives for selective targeting of Gαi/s in the future.
异三聚体 G 蛋白分为四个亚家族,在信号转导中发挥关键作用。它们在 G 蛋白偶联受体 (GPCR) 被激活后,将细胞外信号传递到细胞内效应物,超过 30%的 FDA 批准药物的靶点是 GPCR。然而,将 G 蛋白作为药物靶点是一种很有吸引力的选择,例如,当 G 蛋白独立于相应的 GPCR 发挥作用时,或者在涉及大量不同 GPCR 的复杂多态性疾病的情况下。与 Gαq 不同,迄今为止,通过合适的化学化合物靶向 Gαi/s 的努力尚未成功。在这里,我们进行了一项全面的分析,研究了 Gαi/s 与其上下游相互作用伙伴的最重要的界面区域。通过将现有的化合物和已进行的方法分配到相应的界面上,对各个界面的成药性进行了排序,为未来选择性靶向 Gαi/s 提供了思路。